Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Profit After Tax: 2016-2024

Historic Profit After Tax for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$298.4 million.

  • Crinetics Pharmaceuticals' Profit After Tax fell 69.33% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$423.1 million, marking a year-over-year decrease of 52.24%. This contributed to the annual value of -$298.4 million for FY2024, which is 39.10% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Profit After Tax stood at -$298.4 million for FY2024, which was down 39.10% from -$214.5 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Profit After Tax ranged from a high of -$73.8 million in FY2020 and a low of -$298.4 million during FY2024.
  • For the 3-year period, Crinetics Pharmaceuticals' Profit After Tax averaged around -$225.6 million, with its median value being -$214.5 million (2023).
  • Data for Crinetics Pharmaceuticals' Profit After Tax shows a maximum YoY slumped of 52.28% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Profit After Tax stood at -$73.8 million in 2020, then tumbled by 45.83% to -$107.6 million in 2021, then tumbled by 52.28% to -$163.9 million in 2022, then tumbled by 30.88% to -$214.5 million in 2023, then plummeted by 39.10% to -$298.4 million in 2024.